Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8465610 | 0.84 | PDE4A (0.54) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL6274785 | 0.82 | PDE4A (0.52) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL3708519 | 0.82 | PDE4A (0.44) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL3709949 | 0.82 | PDE4A (0.44) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL4395659 | 0.82 | PDE4A (0.44) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL1656749 | 0.81 | PDE4A (0.50) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL4393096 | 0.80 | PDE4A (0.42) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL4395512 | 0.79 | PDE4A (0.59) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL3289378 | 0.79 | PDE4A (0.48) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 | |
| SCHEMBL1005420 | 0.79 | PDE4A (0.59) | PDE4AUSP2SLCO1B1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10612029-B2 | Microorganisms and methods for the production of aniline | GENOMATICA, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190328719-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH FLUPIRTINE | OVID THERAPEUTICS INC. | 2019-10-31 | — | — | US | disclosed |
| CN-110225754-A | Method for treating developmental disorders and/or seizure disorders with flupirtine | 奥维德医疗公司 | 2019-09-10 | — | — | CN | disclosed |
| EP-3528807-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH FLUPIRTINE | Ovid Therapeutics Inc (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190153454-A1 | MICROORGANISMS FOR THE PRODUCTION OF ANILINE | GENOMATICA, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190105308-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH FLUPIRTINE | OVID THERAPEUTICS INC (US) | 2019-04-11 | — | — | US | disclosed |
| US-10167477-B2 | Microorganisms and methods for the production of aniline | GENOMATICA, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180195076-A1 | MICROORGANISMS FOR THE PRODUCTION OF ANILINE | GENOMATICA, INC. | 2018-07-12 | — | — | US | disclosed |
| WO-2018098111-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH FLUPIRTINE | OVID THERAPEUTICS INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20180140586-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH FLUPIRTINE | OVID THERAPEUTICS INC. | 2018-05-24 | — | — | US | disclosed |
| US-20100120906-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010008894-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010009433-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090326059-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2086925-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2061465-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008066900-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008024398-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328719-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH FLUPIRTINE | GRIN2C, SYNGR2, GRIK5 | PDE4A 420/4885USP2 3408/4885SLCO1B1 3757/4885 |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | KCNQ2, KCNQ1, KCNQ5 | PDE4A 1603/4885USP2 3947/4885SLCO1B1 667/4885 |
| US-20100120906-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | HNMT, HCN3, HRH4 | PDE4A 786/4885USP2 1797/4885SLCO1B1 921/4885 |
| US-20190105308-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH FLUPIRTINE | GRIN2C, SYNGR2, GRIK5 | PDE4A 420/4885USP2 3408/4885SLCO1B1 3757/4885 |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | KCNB2, KCNB1, KCNA1 | PDE4A 1030/4885USP2 4544/4885SLCO1B1 818/4885 |
| US-20180140586-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH FLUPIRTINE | GRIN2C, SYNGR2, GRIK5 | PDE4A 420/4885USP2 3408/4885SLCO1B1 3757/4885 |
| US-20090326059-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCND2, KCNB2, KCNAB1 | PDE4A 948/4885USP2 4248/4885SLCO1B1 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.